PCSK9 and atherosclerosis: There are less data available on the timing of PCSK9 inhibitor treatment initiation after an ASCVD event; however, data from a sub-study of the FOURIER trial showed improved prognosis if evolocumab treatment was initiated within 1 year after an myocardial infarction, as compared with a delayed initiation of therapy (43).